Clinical Trials Logo

Long QT Syndrome Type 3 clinical trials

View clinical trials related to Long QT Syndrome Type 3.

Filter by:
  • None
  • Page 1

NCT ID: NCT02300558 Terminated - Clinical trials for Long QT Syndrome Type 3

Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

Start date: December 17, 2014
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the effect of oral eleclazine on mean daytime QTcF interval after 24 weeks of treatment with elecalzine in participants with long QT syndrome Type 3. During the single-blind treatment period (24 weeks), participants will receive eleclazine and/or eleclazine placebo. Following the single-blind treatment period, participants who have not permanently discontinued study drug will be eligible, at the discretion of the investigator, to continue receiving eleclazine during an open-label extension (OLE) phase.

NCT ID: NCT01728025 Recruiting - Clinical trials for Long QT Syndrome Type 3

Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine

Start date: October 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether ranolazine will reduce the risk of arrhythmic events in patients with long QT syndrome type 3.